Lung Cancer Dispatch
4.5K views | +0 today
Follow
Lung Cancer Dispatch
News for Patients and Physicians
Curated by Cancer Commons
Your new post is loading...
Your new post is loading...
Suggested by Cancer Commons
Scoop.it!

New Clinical Trial Investigates Novel Lung Cancer 'Nanomedicine'

New Clinical Trial Investigates Novel Lung Cancer 'Nanomedicine' | Lung Cancer Dispatch | Scoop.it

A new phase II clinical trial is investigating the new cancer drug BIND-014 as a second-line treatment for non-small cell lung cancer (NSCLC). BIND-014 is part of a group of 'nanoengineered' drugs called Accurins, which consist of: 1) targeting particles that direct them preferentially to the disease site–in the case of BIND-014, these particles bind to PSMA, a protein expressed on cancer cells; 2) a 'stealth layer' protecting them from the body's immune system; 3) a controlled-release structure ensuring that the 'payload' is released at the optimal rate; and 4) the drug's actual payload–in the case of BIND-014, the chemotherapy agent docetaxel (Taxotere). Accurins are designed to maximize the drug concentration delivered to the tumor, while minimizing toxicity to healthy tissues.

Cancer Commons's insight:

Boston.com | Jul 29, 2013

more...
No comment yet.
Suggested by Cancer Commons
Scoop.it!

Inhalable Chemotherapy May Offer Superior Lung Cancer Treatment

Inhalable Chemotherapy May Offer Superior Lung Cancer Treatment | Lung Cancer Dispatch | Scoop.it

A new drug delivery system attaches chemotherapy drugs to nanocarriers–microscopically tiny particles–to create an inhalable lung cancer treatment. Because this approach delivers drugs directly into the lung, it minimizes their effects on the rest of the body, potentially reducing side effects. The drugs also reach the lungs in their most potent form, without being degraded after injection into the bloodstream during transport to the lung. In addition to chemotherapy, the nanocarriers can also deliver another type of small particle, called siRNA, designed to combat drug resistance. In a recent study, this inhalable combination treatment drastically shrank lung cancer tumors implanted in mice, and resulted in 83% of the drug being delivered to the lung, compared to 23% when the drug was injected. However, further testing is necessary before this treatment can be investigated in human clinical trials.

Cancer Commons's insight:

ScienceDaily | May 22, 2013

more...
No comment yet.